Evaluation of Limited Sampling Strategies for Estimation of 12-Hour Mycophenolic Acid Area Under the Plasma Concentration???Time Curve in Adult Renal Transplant Patients
- 1 October 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 22 (5) , 549-554
- https://doi.org/10.1097/00007691-200010000-00008
Abstract
Mycophenolate mofetil, the oral prodrug of mycophenolic acid, is indicated as immunosuppressive therapy after renal transplantation. To aid in the investigation of pharmacokinetic–pharmacodynamic relationships of mycophenolic acid in the clinical setting, limited blood sampling strategies have been proposed, and models from these developed, for the estimation of mycophenolic acid area under the concentration–time curve (AUC). In the current study, the authors investigated the predictive performance of six published models to estimate AUC. A total of 49 profiles from 25 renal transplant patients were used to test each model's performance against a full 14 time-point AUC. A wide range of agreement was found when predicted AUCs were compared with full AUCs using linear regression analysis (range:r2 = 0.499 to 0.836). Model 1, which uses 4 time-points over 6 hours, was found to be superior to all other models. The range of time-points used in this model takes into account patients with variable absorption. This model should be further tested on data sets from other centers. The relatively poor performance of the other models may be caused by their inability to describe the peak concentration in these patients. Caution is warranted when using limited sampling strategies on patients whose absorption of mycophenolic acid is altered, compared with those of the pharmacokinetic profiles from which the model was developed.Keywords
This publication has 21 references indexed in Scilit:
- The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipientsClinical Pharmacology & Therapeutics, 1999
- The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation*Clinical Pharmacology & Therapeutics, 1998
- Pharmacokinetics of mycophenolic acid after renal transplantationTransplantation Proceedings, 1998
- Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejectionClinical Biochemistry, 1998
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998
- Effect of Mycophenolic Acid Glucuronide on Inosine Monophosphate Dehydrogenase ActivityTherapeutic Drug Monitoring, 1997
- A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1996
- Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous AdministrationThe Journal of Clinical Pharmacology, 1996
- Mechanism of Action of Mycophenolate MofetilTherapeutic Drug Monitoring, 1995
- Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejectionThe Lancet, 1995